1 BTC
=
- USD
SELLAS Life Sciences Group, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About SELLAS Life Sciences Group, Inc. Common Stock
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Market Statistics
Trading Metrics
How to Buy SLS
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy SLS
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articles
SELLAS presented preclinical data showing that its CDK9 inhibitor SLS009 demonstrated potent anti-proliferative activity in ASXL1 mutant colorectal cancer cell lines, suggesting its potential as a targeted therapy for this patient population.
The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.
The article discusses recent advancements in cancer research and treatment, including promising results from clinical trials of various cancer therapies developed by companies like Oncolytics Biotech, Celcuity, Genenta Science, Sellas Life Sciences, and Amgen.
